Table 3 Economic evaluation characteristics of all included studies

Campbell et al. (33)

Strategy 3 testing

$124,800,000

$67,800,000

$57,000,000 ^a

$113,300,000 ^a

-$56,300,000

$19,877·19 ^a

Strategy 3 + Strategy 1 + Status Quo testing

$203,700,000

$135,900,000 ^a

$218,000,000 ^a

-$82,100,000

$16,041·21 ^a

Church et al. (28)

Duration of influenza outbreak (days)

$69·52

9 ^a

$98·55

16 ^a

-$29·03

-7 ^a

2,411·30 ^a

Hutton et al. (31)

CAUTI events

$139,948

15·5

$173,986

24·2

-$34,038

-8·7

-$15,136

-$18,902 ^a

2.56 ^a

$4,446·79 ^a

Hospitalisation due to CAUTI events

6·8

9·7

-2·9

-$39,180

-$5,142 ^a

0.85 ^a

$11,510·66 ^a

QALYs lost from CAUTI events

0·35

0·55

-0·2

Total

54,316

$20,278

-$15,957·45 ^a

Lee et al. (34)

Number of CRE Infections

All facilities eligible

$303,300,000

2,896

$325,500,000

3186

-$22,200,000 ^a

-290 ^a

0·13 ^a

Geographic constraint

$298,400,000

2,853

-$27,100,000 ^a

-333 ^a

0·12 ^a

Number of CRE-Attributable Deaths

All facilities eligible

$303,300,000

348

383

-$22,200,000 ^a

-35 ^a

0·02 ^a

Geographic constraint

$298,400,000

343

-$27,100,000 ^a

-40 ^a

0·01 ^a

QALYs Lost

All facilities eligible

$303,300,000

3,679

4,049

-$22,200,000 ^a

-370 ^a

0·17 ^a

Geographic constraint

$298,400,000

3,626

-$27,100,000 ^a

-423 ^a

0·16 ^a

Li et al. (32)

LYs gained

Xpert

$162

11·1952

$121

11·1907

$41

0·0045

1·1 ^a

CXR

$168

11·1942

$47

0·0035

0·74 ^a

LTBI/TB screening

$430

11·2003

$309

0·0096

0·31 ^a

QALYs gained

Xpert

$162

11·1702

11·1634

$41

0·0068

1·66 ^a

CXR

$168

11·1687

$47

0·0053

1·13 ^a

LTBI/TB screening

$430

11·1792

$309

0·0158

0·51 ^a

Marchand et al. (27)

Cases of TB predicted (conversion rate 0.6%)

$6,100

0·52

$3,204

1·28

$2,896

-0·76

-2·62 ^a

TB-related deaths predicted (conversion rate 0.6%)

0·24

0·55

-0·31

-1·07 ^a

Cases of TB predicted (conversion rate 0)

$5,965

0·52

$2,283

0·95

$3,682

-0·43

-1·17 ^a

TB-related deaths predicted (conversion rate 0)

0·21

0·40

-0·19

-0·52 ^a

Salmerón et al. (35)

PCR and quarantines avoided

$14,753·5

Sansone and Bravo (36)

UTI rate per quarter

$23,125

2·3%

$33,907

3·3% ^a

-$10,782 ^a

-1% ^a

0·01 ^a

Trick et al. (29)

MRSA case patients’ percentage among those at risk

$2,415

20%

$6,066

18%

-$3,651 ^a

2% ^a

-0·05 ^a

ESBL KP case patients’ percentage among those at risk

10%

17%

-7% ^a

0·19 ^a

ESBL EC case patients’ percentage among those at risk

15%

11%

4% ^a

0·11 ^a

VRE case patients’ percentage among those at risk

6·8%

8·1%

-1·3% ^a

0·04 ^a

Verma et al. (30)

Cases/1000 entrants - LTBI screening

$202,822

4·6

$124,416

5·3

$78,405

-0·7 ^a

-0·000009 ^a

Cases/1000 entrants - Active TB screening

$655,649

4·5

5·3

$531,233

-0·8 ^a

-0·000002 ^a